Heart Failure Clinical Trial
— IMPROVE-MCOfficial title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Immunosuppression in Biopsy-proven Virus Negative Myocarditis or Inflammatory Cardiomyopathy
Myocarditis can result in numerous complications, but there is paucity of data regarding optimal therapy, short- and long-term effects of possibly effective immunosuppressive therapy. The IMPROVE-MC study will provide high-quality scientific data about efficacy and safety of immunosuppressive therapy, non-invasive (MRI, biomarkers) and invasive diagnostics tests (endomyocardial biopsy), and prognosis in myocarditis. The objective of this multicenter, prospective, randomized, double-blind placebo-controlled trial is to assess the efficacy and safety of 12 - month treatment with prednisone and azathioprine comparing to placebo on top of guideline-recommended medical therapy in patients with biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy and reduced ejection fraction (LVEF ≤ 45%). The study will also assess persistence of the treatment effects after 12 months.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | March 30, 2028 |
Est. primary completion date | September 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: To be eligible for inclusion in this study, patient must fulfill all of the following inclusion criteria: 1. Written informed consent to participate in the IMPROVE-MC study (including two EMBs and two cardiac CMRs) prior to any evaluation or procedure related to the study. 2. Patient with clinically suspected myocarditis or inflammatory cardiomyopathy (according to the criteria of the ESC Working Group on Myocardial & Pericardial Diseases 2013 and ESC Heart Failure Guidelines 2021); OR/ AND, Patients with already diagnosed active myocarditis (lymphocytic or eosinophilic) or inflammatory cardiomyopathy who will undergo diagnostic right ventricular (or/and left ventricular) EMB during the screening; OR / AND, Patients with already diagnosed active myocarditis (lymphocytic or eosinophilic) or inflammatory cardiomyopathy confirmed by right ventricular (or/and left ventricular) EMB that was performed according to the IMPROVE-MC study protocol within 3 months from screening. 3. Men or women aged 18-65. Women of childbearing age must have a negative pregnancy test result. Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (with a failure rate of < 1% per year) for the duration of the study (from the time they sign consent) and for 8 weeks after the last dose of study treatment to prevent pregnancy. Patients agreeing to total sexual abstinence can also be included, assuming it is their usual lifestyle. Women are considered postmenopausal and without the potential to have a child if they have 12 months of natural (spontaneous) amenorrhea with an appropriate clinical picture (e.g. appropriate age, history of vasomotor symptoms) or have undergone bilateral surgical ovariectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of ovariectomy alone, only if the reproductive status of the woman has been confirmed by assessing hormone levels. 4. No significant improvement in clinical condition or worsening course of the disease despite the standard treatment in the investigator's opinion, in the last = 3 months prior to the screening period. 5. LVEF 10 - 45% measured by echocardiogram taken during the screening period 1. No significant LVEF improvement in the last =3 months prior to the screening period in the investigator's opinion. 2. LVEF should be measured under stable conditions as assessed by the investigator. 3. LVEF should be verified in the CORE-LAB. 6. Histological and immunohistochemical evidence of active myocarditis (lymphocytic or eosinophilic) OR inflammatory cardiomyopathy during the screening period (EMB during the screening or within last 3 months). 7. Absence of cardiotropic viruses in cardiac tissue at PCR analysis during the screening period (EMB during the screening or within last 3 months). Exclusion Criteria: Patients fulfilling any of the following exclusion criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients. 1. Presence of contraindications to immunosuppressive therapy with steroids and/ or azathioprine (including hypersensitivity to azathioprine/ 6-mercaptopurine or prednisone, mainly untreated systemic infection, uncontrolled diabetes, poorly controlled endocrine diseases, osteoporosis, active gastric or duodenal ulcer, uncontrolled hypertension, leukocytopenia (leukocyte counts <4 x 109/l), neutropenia (neutrophils <1.5 x 109/l), thrombocytopenia (platelet levels <130 x 109/l), anemia (hemoglobin levels <11 g/dl). 2. Positive clinical screening for active infections, including HIV, HBV, HCV. Assessment of tuberculosis infection should be considered before screening, according to the local epidemiologic status and according to investigator's opinion. After careful evaluation of the activity of the infection (or cure of the infection), the patient may continue participation in the study according to investigator's opinion. 3. Another specific cause of heart failure (including severe congenital, valvular, hypertensive, and/or coronary artery disease) that could justify the severity of cardiac dysfunction. 4. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), storage diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, genetic hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or known pericardial constriction. 5. Diagnosed or suspected cardiac sarcoidosis or giant cell myocarditis, autoimmune/ systemic immune-mediated disease (i.e. granulomatosis with polyangiitis, lupus erythematosus) that might require specific immunosuppressive therapy. Recent, current or expected future need for long-term use of immunosuppressive therapy with steroids and/ or azathioprine and/ or other immunosuppressive agent (caution - short-term course of steroids [i.e. for asthma attack, occasional topical applications] is not an exclusion). 6. NYHA class I and IV. 7. Subjects with body mass index >40 kg/m2 or body weight <50 kg. 8. Pregnancy, lactation or women who plan to become pregnant during the trial. Lack of consent to the use of effective forms of contraception. 9. Any documented or suspected active malignant neoplasm or history of malignant neoplasm within the 5 years prior to the screening period. 10. History of cytostatic therapy or radiotherapy. 11. Liver disease defined as any of the following: AST or ALT or ALP above 3x ULN; bilirubin >1.5 mg/dL. 12. Impaired renal function, defined as eGFR <45 mL / min / 1.73 m2 (CKD-EPI) measured under stable condition or requiring dialysis. Conditionally, according to the investigator's decision, patients with eGFR 40-45 ml / min / 1.73 m2 may be included. 13. The need or refusal to stop taking any drug considered to interfere with the safe course of the study (e.g., allopurinol). 14. Currently implanted or planned VAD, CRT or heart transplant. 15. Patients with pacemaker or ICD requiring a high percentage of ventricular pacing (>30%) which could influence the result of LVEF measurement in the investigator's opinion. 16. Gastrointestinal surgery or gastrointestinal disorder that could interfere with trial drug(s) absorption in the investigator's opinion. 17. History or presence of any other disease with a life expectancy <3 years. 18. Any contraindications or intolerance to CMR*, including but not limited to: 1. the presence of cardiac implantable electronic device implanted <6 weeks ago; 2. pacing capture threshold out of the normal range; 3. additional cardiac leads (particularly abandoned pacemaker leads), epicardial leads, fractured leads, additional components such as lead adapters or lead extension; 4. aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body that could be contraindication to CMR; 5. presence of claustrophobia making impossible to perform CMR; 6. or any other clinical history or study that determines that, in the investigator's judgment, the performance of an CMR may pose a potential risk to the patient. 19. Immunization with live organism vaccines in the last 3 months prior to randomization. 20. Chronic alcohol or drug abuse or non-compliance with medical recommendations or any condition that, in the investigator's opinion, makes patient an unreliable trial subject or unlikely to complete the trial. 21. Use of other investigational drugs at the time of enrollment, or within 30 days, or within 5 half-lives of enrollment, whichever is longer. 22. Subjects directly involved in the execution of this protocol. - CMR in non-conditional CIED proved to be safe. CMR in CIED patients will be performed according to HRS 2017 and ESC Pacing 2021 guidelines |
Country | Name | City | State |
---|---|---|---|
Poland | First Department of Cardiology, Medical University of Warsaw | Warsaw |
Lead Sponsor | Collaborator |
---|---|
Medical University of Warsaw |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LVEF at 12 - months. | Left ventricle ejection fraction (LVEF) at 12 - months. | 12- months | |
Secondary | Proportion of patients who responded to immunosuppressive therapy. | Proportion of patients who responded to immunosuppressive therapy as defined by an LVEF increase of =10% over time. | 12-months | |
Secondary | LVEF at 12 months in subgroups of patients with baseline LVEF =30% and >30% | 12 months | ||
Secondary | Change in the LV end-systolic and end-diastolic dimensions as well as the LV end-systolic and end-diastolic volumes over time. | 12-months | ||
Secondary | Change from baseline in NYHA class over time. | 12-months | ||
Secondary | Occurrence of adjudicated heart failure decompensation (hospitalization or ambulatory visit). | 12-months | ||
Secondary | Change from baseline in percentage of patients in NYHA III/IV and NYHA II class over time. | Change from baseline in percentage of patients in NYHA III/IV and NYHA II class over time (compared to baseline and to the end of treatment) | assessed up to 24th month from the randomization | |
Secondary | Occurrence of need for diuretic i.v. administration. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in 6 minute walk test (6MWT) distance over time. | assessed up to 24th month from the randomization | ||
Secondary | Time to first adjudicated hospitalization for heart failure. | assessed up to 24th month from the randomization | ||
Secondary | Time to first all-cause hospitalization. | assessed up to 24th month from the randomization | ||
Secondary | Occurrence (first and recurrent) of all-cause hospitalization, heart failure hospitalization, heart failure outpatient visit, myocarditis or inflammatory cardiomyopathy recurrence, all-cause death, heart transplantation, implantation of cardiac device | Occurrence (first and recurrent) of all-cause hospitalization, heart failure hospitalization, heart failure outpatient visit, myocarditis or inflammatory cardiomyopathy recurrence, all-cause death, heart transplantation, implantation of cardiac device (pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization therapy, ventricular assist device) assessed in combination or independently. | assessed up to 24th month from the randomization | |
Secondary | New onset atrial fibrillation (AF). | assessed up to 24th month from the randomization | ||
Secondary | New onset sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). | assessed up to 24th month from the randomization | ||
Secondary | =50% reduction from baseline in ventricular ectopic beats (VEBs) number in 48h Holter monitoring over time. | assessed up to 24th month from the randomization | ||
Secondary | =50% reduction from baseline in nonsustained VT number in 48h Holter monitoring over time. | assessed up to 24th month from the randomization | ||
Secondary | =50% reduction from baseline in AF burden in 48h Holter monitoring over time. | assessed up to 24th month from the randomization | ||
Secondary | Changes from baseline in CMR results | Changes from baseline in CMR results (early gadolinum enhancement (EGE), late gadolinum enhancement (LGE), edema, LV dimensions and volumes, T1/T2 mapping) after one-year. | assessed up to 24th month from the randomization | |
Secondary | Changes from baseline in concentration of biomarkers of fibrosis and myocardial necrosis (troponin I, NT-proBNP, sST2, Gal-3) over time. | assessed up to 24th month from the randomization | ||
Secondary | Qualitative and quantitative change from baseline in inflammatory infiltration, human leukocyte antigen (HLA) expression and fibrosis in EMB after one-year. | after 12- months | ||
Secondary | Change from baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) overall summary score over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) total symptom score over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) individual domains over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) based on patient-preferred outcome over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in SF-36 (36-Item Short Form Survey) questionnaire overall summary score over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in PGI-I (Patients Global Impression of Improvement) scale over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in CGI-I (Clinical Global Impressions - Improvement) scale over time. | assessed up to 24th month from the randomization | ||
Secondary | Change from baseline in health economic analysis by HCRU (Healthcare Resource Utilization). | assessed up to 24th month from the randomization | ||
Secondary | Occurrence of need for inotropic drugs/nitroglycerin i.v. administration | Occurrence of need for inotropic drugs/nitroglycerin i.v. administration | assessed up to 24th month from the randomization | |
Secondary | LVEF at 24 months | LVEF at 24 months (maintenance or further improvement). | compared to baseline and/or to the end of treatment) analyzed during follow up (13-24 months) | |
Secondary | LVEF at 24 months in subgroups of patients with baseline LVEF =30% and >30% | LVEF at 24 months (maintenance or further improvement) in subgroups of patients with baseline LVEF =30% and >30% | compared to baseline and/or to the end of treatment) analyzed during follow up (13-24 months) | |
Secondary | Change in the LV end-systolic and end-diastolic dimensions as well as the LV end-systolic and end-diastolic volumes over time. | compared to baseline and/or to the end of treatment) analyzed during follow up (13-24 months) | ||
Secondary | Change in NYHA class over time | compared to baseline and/or to the end of treatment) analyzed during follow up (13-24 months) | ||
Secondary | Occurrence of adjudicated heart failure decompensation (hospitalization or ambulatory visit). | analyzed during follow up (13-24 months) | ||
Secondary | Application of mechanical circulatory support (i.e. ECMO). | assessed up to 24th month from the randomization | ||
Secondary | =50% increase from the end of treatment in VEBs number in 48h Holter monitoring over time. | assessed from the end of treatment up to 24th months from the randomization | ||
Secondary | =50% increase from the end of treatment in nonsustained VT number in 48h Holter monitoring over time | assessed from the end of treatment up to 24th months from the randomization | ||
Secondary | =50% increase from the end of treatment in AF burden in 48h Holter monitoring over time | assessed from the end of treatment up to 24th months from the randomization | ||
Secondary | Changes in tricuspid annular plane systolic excursion | Changes in tricuspid annular plane systolic excursion (reported in centimeters) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in dimensions of the heart cavities | Changes in dimensions of the heart cavities (ventricles and atria; reported in centimeters) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in volumes of the heart cavities | Changes in volumes of the heart cavities (ventricles and atria; reported in milliliters) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in thickness of left and right ventricles | Changes in thickness of left and right ventricles (reported in centimeters) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in tissue Doppler velocities (medial and lateral) of the mitral annulus | Tissue Doppler velocities (medial and lateral) of the mitral annulus (reported in centimeters per second) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in strain of heart cavities | Changes in strain of heart cavities (ventricles and atria; reported as a percentage) over time. | assessed up to 24th months from the randomization | |
Secondary | Changes in concentration of biomarkers of fibrosis and myocardial necrosis (troponin I, NT-proBNP) over time | assessed up to 24th months from the randomization | ||
Secondary | Changes in concentration of anti-heart autoantibodies (AHA) over time | assessed up to 24th months from the randomization | ||
Secondary | Change of patients' health status as assessed by the patients self-reported EQ-5D over time. | assessed up to 24th months from the randomization | ||
Secondary | Change in clinical summary score (heart failure symptoms and physical limitations domains) of KCCQ Questionnaire over time | assessed up to 24th months from the randomization | ||
Secondary | Cost-effectiveness analysis | Pharmacoeconomic analysis based on questionnaires (SF-36, KCCQ, EQ-5D-5L, PGI, CGI, HCRU) and patient prognosis (including adverse event rates, hospitalizations, death, worsening of heart failure, arrhythmias, drug-related adverse events, change in LVEF and NYHA class, gain of QALY). | assessed up to 24th months from the randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|